Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Achievement and IL28B[original query] |
|---|
| Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology (Baltimore, Md.) 2011 Sep 54 (3): 772-80. Mangia Alessandra, Thompson Alexander J, Santoro Rosanna, Piazzolla Valeria, Copetti Massimiliano, Minerva Nicola, Petruzzellis Daniela, Mottola Leonardo, Bacca Donato, McHutchison John |
| Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antiviral therapy 2012 17 (5): 823-31. Petta Salvatore, Ferraro Donatella, Cammà Calogero, Cabibi Daniela, Di Cristina Antonietta, Di Marco Vito, Di Stefano Rosa, Grimaudo Stefania, Mazzola Alessandra, Levrero Massimo, Scazzone Concetta, Craxì Anton |
| The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver international : official journal of the International Association for the Study of the Liver 2012 Jul 32 (6): 962-9. Huang Jee-Fu, Yu Ming-Lung, Huang Chung-Feng, Juo Suh-Hang Hank, Dai Chia-Yen, Hsieh Ming-Yen, Hou Nei-Jen, Yeh Ming-Lun, Hsieh Meng-Hsuan, Yang Jeng-Fu, Lin Zu-Yau, Chen Shinn-Chern, Shin Shyi-Jang, Chuang Wan-Lo |
| Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2012 Dec . Huang CF, Yu ML, Kao JH, Tseng TC, Yeh ML, Huang JF, Dai CY, Lin ZY, Chen SC, Wang LY, Juo SH, Chuang WL, Liu CH |
| Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. AIDS (London, England) 2012 Nov . Rallon NI, Lopez-Fernandez LA, Garcia MI, Benguria A, Fiorante S, Soriano V, Benito JM |
| Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. Therapeutic drug monitoring 2012 Dec 34 (6): 6. D?avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G |
| The reduced predictive value of interleukin 28b gene polymorphisms in a cohort of patients with thyroiditis developed during antiviral therapy for chronic hepatitis C: a preliminary study. Hepatitis monthly 2012 Aug 12 (8): e6036. Tran Huy A, Jones Tracey L, Ianna Elizabeth A, Gibson Robert A, Reeves Glenn E |
| Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. BioMed research international 2013 2013 580796. Aghemo Alessio, Degasperi Elisabetta, Rumi Maria Grazia, Galmozzi Enrico, Valenti Luca, De Francesco Raffaele, De Nicola Stella, Cheroni Cristina, Grassi Eleonora, Colombo Massi |
| Impact of IL12B gene rs 3212227 polymorphism on fibrosis, liver inflammation, and response to treatment in genotype 4 Egyptian hepatitis C patients. Disease markers 2013 35 (5): 431-7. Youssef Samar Samir, Mostafa Abd El-Aal Asmaa, Saad Amr, Omran Moataza Hassan, El Zanaty Taher, Mohamed Seif Sam |
| Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area. Intervirology 2013 Jan . Chung HJ, Lee JW, Kim YS, Lee JI |
| Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype. Hepatology research : the official journal of the Japan Society of Hepatology 2015 Apr 45 (4): 387-96. Abe Hiroshi, Tsubota Akihito, Shimada Noritomo, Atsukawa Masanori, Kato Keizo, Takaguchi Koichi, Asano Toru, Chuganji Yoshimichi, Sakamoto Choitsu, Toyoda Hidenori, Kumada Takashi, Ide Tatsuya, Sata Michio, Aizawa Yosh |
| Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. Antiviral therapy 2015 20 (3): 335-41. Cusato Jessica, Allegra Sarah, Boglione Lucio, De Nicolò Amedeo, Baietto Lorena, Cariti Giuseppe, Di Perri Giovanni, D'Avolio Anton |
| Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients. Cytokine 2015 Aug 74 (2): 268-72. Fathy Mona M, Abo Taleb Mohamed E, El Hawary Mohamed S, Nabih Mona I, Aref Wael M, Makhlouf Manal |
| The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepatitis monthly 2016 Jan 16 (1): e32703. Behnava Bita, Sharafi Heidar, Keshvari Maryam, Pouryasin Ali, Mehrnoush Leila, Salimi Shima, Karimi Elizee Pegah, Ghazimoghaddam Mehran, Alavian Seyed Moay |
| Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus. World journal of gastroenterology 2016 Nov 22 (41): 9186-9195. Domagalski Krzysztof, Paw?owska Ma?gorzata, Zale?na Agnieszka, Pilarczyk Ma?gorzata, Rajewski Pawe?, Halota Waldemar, Tretyn Andrz |
| Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. Journal of postgraduate medicine 0 62 (1): 20-5. Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Aizawa |
| The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study. Acta medica Indonesiana 2019 8 51 (2): 128-136. Kurniawan Juferdy, Gani Rino A, Djauzi Samsuridjal, Ibrahim Fera, Harimurti Kuntjoro, Nafrialdi Nafrialdi, Imannuel Suzan |
- Page last reviewed:Feb 1, 2024
- Content source: